Novo Nordisk ® reased risk of developing severe ening and costly for society ople with obesity are ion medication Global healthcare cost related to obesity expected to increase by 20% by 2025 +20% d tively anaged 1 2% treated 2 USD ~1.0 trillion USD ~1.2 trillion 2020 2025
Download PDF file